Search Results - "Varsamis, Zacharenia A."

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity by Gozgit, Joseph M., Vasbinder, Melissa M., Abo, Ryan P., Kunii, Kaiko, Kuplast-Barr, Kristy G., Gui, Bin, Lu, Alvin Z., Molina, Jennifer R., Minissale, Elena, Swinger, Kerren K., Wigle, Tim J., Blackwell, Danielle J., Majer, Christina R., Ren, Yue, Niepel, Mario, Varsamis, Zacharenia A., Nayak, Sunaina P., Bamberg, Ellen, Mo, Jan-Rung, Church, W. David, Mady, Ahmed S.A., Song, Jeff, Utley, Luke, Rao, Patricia E., Mitchison, Timothy J., Kuntz, Kevin W., Richon, Victoria M., Keilhack, Heike

“…PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto substrates to change their function. Here, we identify PARP7 as a negative…”
Get full text

Abstract 1021: Investigating the mechanism of PARP7 inhibition in type I interferon signaling by arrayed CRISPR screening by Gui, Bin, Abo, Ryan, Flynn, Patrick, Lu, Alvin Z., Mo, Jan-Rung, Gozgit, Joseph M., Vasbinder, Melissa M., Varsamis, Zacharenia A., Santospago, Andrew, Richon, Victoria M., Kuntz, Kevin W., Keilhack, Heike, Mitchison, Timothy J., Niepel, Mario

“…Abstract Genomic instability in cancer cells leads to cellular stress through the accumulation of aberrant nucleic acid species in the cytosol. We have shown…”
Get full text

Abstract 3405: PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition leads to tumor regression by Gozgit, Joseph M., Vasbinder, Melissa M., Abo, Ryan P., Kunii, Kaiko, Kuplast-Barr, Kristy G., Gui, Bin, Lu, Alvin Z., Swinger, Kerren K., Wigle, Tim J., Blackwell, Danielle J., Majer, Christina R., Ren, Yue, Niepel, Mario, Varsamis, Zacharenia A., Nayak, Sunaina P., Bamberg, Ellen, Mo, Jan-Rung, Church, William, Song, Jeff, Utley, Luke, Rao, Patricia E., Mitchison, Timothy J., Kuntz, Kevin W., Richon, Victoria M., Keilhack, Heike

“…Abstract Targeting cytosolic nucleic acid sensing pathways and the Type I interferon (IFN) response is an emerging therapeutic strategy being explored in…”
Get full text

Abstract DDT02-01: RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways by Vasbinder, Melissa M., Gozgit, Joseph M., Abo, Ryan P., Kunii, Kaiko, Kuplast-Barr, Kristy G., Gui, Bin, Lu, Alvin Z., Swinger, Kerren K., Wigle, Tim J., Blackwell, Danielle J., Majer, Christina R., Ren, Yue, Niepel, Mario, Varsamis, Zacharenia A., Nayak, Sunaina P., Bamberg, Ellen, Mo, Jan-Rung, Church, W David, Song, Jeff, Utley, Luke, Rao, Patricia E., Mitchison, Timothy J., Kuntz, Kevin W., Richon, Victoria M., Keilhack, Heike

“…Abstract RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways PARP7 is a monoPARP that…”
Get full text

Abstract 2154: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models by Molina, Jennifer R., Gozgit, Joseph M., Vasbinder, Melissa M., Abo, Ryan P., kunii, Kaiko, Kuplast-Barr, Kristy G., Gui, Bin, Nayak, Sunaina P., Minissale, Elena, Swinger, Kerren K., Wigle, Tim J., Lu, Alvin Z., Blackwell, Danielle J., Majer, Christina R., Ren, Yue, Bamberg, Ellen, Niepel, Mario, Mo, Jan-Rung, Church, William D., Mady, Ahmed S., Song, Jeff, Varsamis, Zacharenia A., Utley, Luke, Rao, Patricia E., Mitchison, Timoty J., Kuntz, Kevin W., Richon, Victoria M., McEachern, Kristen, Keilhack, Heike

“…Abstract Targeting cytosolic nucleic acid sensing pathways to activate the Type I interferon (IFN) response is an emerging therapeutic strategy being explored…”
Get full text